The reduction in total operating revenue reflects the discontinuation of the AstraZeneca collaboration in 2023 ... Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that ...

AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September 2024 is now available on the company's ...

STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - Septem ...

ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis to clinical trials could identify patients ...

Pfizer has made a new and improved bid to acquire AstraZeneca with an offer worth £69.3 billion pounds ($116.6 billion) or £55 a share – and says this is its best and final offer for the firm.

Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China’s ...

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen management will participate in a ...

The global cold, cough, and sore throat remedy market is poised for steady growth, with a projected CAGR of 3.40% from 2024 to 2034. The market is estimated to be valued at US$ 42,618.7 million in ...